Q2 FY2026 · ended Jun 30, 2026 · Revenue $85.39M, +4.4% YoY · Filed Jul 30, 2026
Fulgent Genetics, Inc. (FLGT) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $85.4 million and a net loss of $29.5 million. Free cash flow was -$27.6 million. As of Jun 30, 2026 it held $551.3 million in cash and investments and $7.6 million in total debt.
Revenue
$85.39M
+4.4% vs year-ago quarter
Net income
$-29.53M
-55.8% vs year-ago quarter
Operating cash flow
$-23.76M
+21.3% vs year-ago quarter
Free cash flow
$-27.62M
+25.4% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
27.52M
-10.1% vs year-ago quarter
Net cash
$543.70M
Q2 FY2026
Operating margin
-37.7%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- FLGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- El Monte, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1674930
- Former names
- Fulgent Diagnostics, Inc. (until Jul 15, 2016)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $85.4M | $71.1M | $83.3M | $84.1M | $81.8M |
| Operating income | -$36.1M | -$34.6M | -$36.2M | -$15.3M | -$19.7M |
| Net income | -$29.5M | -$24.8M | -$23.4M | -$6.6M | -$19.0M |
| Operating cash flow | -$23.8M | $7.1M | -$78.1M | $11.1M | -$30.2M |
| Free cash flow | -$27.6M | $1.9M | -$83.1M | $5.1M | -$37.0M |
| Total assets | $1.1B | $1.2B | $1.2B | $1.2B | $1.2B |
| Total liabilities | $93.2M | $112.2M | $106.8M | $93.8M | $88.2M |
| Stockholders' equity | $1.0B | $1.0B | $1.1B | $1.1B | $1.1B |
| Cash and investments | $551.3M | $604.6M | $705.3M | $529.4M | $572.4M |
| Total debt | $7.6M | $8.2M | $5.6M | $5.6M | $5.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | Jun 1, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 1, 2026 | Mar 31, 2026 |
All 668 Fulgent Genetics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.